BDRX News and Press, Biodexa Pharmaceuticals PLC-ADR

2026-04-02 10:33:04 ET Denver, Colorado -A powerful convergence of global energy disruption and emerging technology catalysts is reshaping pockets of the market, with select small-cap names ready to make moves. Shares of Sky Quarry (NASDAQ:SKYQ) have drawn heightened attention as Brent ...

April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceu...

March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharm...

2026-03-18 17:10:29 ET More on Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals Read the full article on Seeking Alpha For further details see: Biodexa Pharmaceuticals announces ADR ratio change

March 9, 2026 Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative pr...

MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical...

February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals P...

January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developi...

2025-12-18 08:43:23 ET More on Biodexa Pharmaceuticals Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals Read the full article on Seeking Alpha For further details see: Biodexa Pharmaceuticals...

December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of dise...